Clinical Activity of Enzalutamide in Docetaxel-Naive and Docetaxel-Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer

摘要

BACKGROUND. Two randomized clinical trials have demonstrated a survival advantage with enzalutamide over placebo in both docetaxel (D)-pretreated and D-naive metastatic castration-resistant prostate cancer (mCRPC) patients. Cross-resistance between androgen receptor-directed therapies and taxanes has been suggested, possibly leading to lower efficacy of enzalutamide in the post-D setting.